Pirbright generates pig flu antibodies that could improve human treatments

The Pirbright Institute has announced a breakthrough that paves the way for first pig antibodies against swine influenza to be used to protect humans against flu. 

Researchers at the Surrey instituted have generated the first pig antibodies against swine influenza (flu) that protect against infection and recognise the same parts of the flu virus as human antibodies.

This indicates they could be used to develop and assess human antibody therapies and their delivery methods. The pig antibodies also have the potential to improve how flu virus evolution is monitored and inform decisions about annual flu vaccine selection, the institute said.

Antibodies form a vital part of the immune system’s response and help to fight off infections by latching on to important parts of invading microorganisms to neutralise them. In the case of flu viruses, many antibodies target a protein on the surface of the virus called haemagglutinin, which then prevents the virus from entering cells and replicating.

Pirbright scientists worked in collaboration with the University of Oxford, The Francis Crick Institute and The Pirbright Livestock Antibody Hub to generate pig antibodies in the laboratory (known as monoclonal antibodies, or mAbs). These are the first pig mAbs to be generated which target the influenza virus.

These mAbs recognise the same two main sites of the flu virus haemagglutinin protein that are targeted by human antibodies, and were found to be just as effective at neutralising the swine flu strain that caused the 2009 pandemic.

Pigs that were treated with one of the mAbs prior to infection were protected from severe disease and the flu virus was eliminated from their lungs. This indicates that the mAbs have great therapeutic potential and could be used to evaluate mAb delivery methods.

The findings in the study, published in PLOS Pathogens, demonstrate that pig mAbs are more closely matched to human antibodies than ferrets, which are more commonly used as models to monitor flu virus evolution and to design human vaccines, and could therefore improve the reliability of human vaccine selection.

Dr Elma Tchilian, Mucosal Immunology Group Leader at Pirbright, said: “These data demonstrate that pigs and humans, which are both natural hosts for influenza viruses, generate very similar immune responses. This makes the pig an excellent translational model for testing novel vaccines and monoclonal antibody delivery methods.”

Professor John Hammond, leader of The Pirbright Livestock Antibody Hub, added: “This work reinforces the use of pigs as powerful model to predict human responses in infection and vaccination.”

This work was supported by the Bill & Melinda Gates Foundation and the Biotechnology and Biological Sciences Research Council (BBSRC), part of UK Research and Innovation (UKRI).

Get Our E-Newsletter - Pig World's best stories in your in-box twice a week
Will be used in accordance with our Privacy Policy

About The Author

Editor of LBM titles Pig World and Farm Business and group editor of Agronomist and Arable Farmer. National Pig Association's webmaster. Previously political editor at Farmers Guardian for many years and also worked Farmers Weekly. Occasional farming media pundit. Brought up on a Leicestershire farm, now work from a shed in the garden in Oxfordshire. Big fan of Leicester City and Leicester Tigers. Occasional cricketer.